Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2354-8. doi: 10.1016/j.bmcl.2011.02.082. Epub 2011 Mar 1.

Abstract

A new series of imidazopyridine CB2 agonists is described. Structural optimization improved CB2/CB1 selectivity in this series and conferred physical properties that facilitated high in vivo exposure, both centrally and peripherally. Administration of a highly selective CB2 agonist in a rat model of analgesia was ineffective despite substantial CNS exposure, while administration of a moderately selective CB2/CB1 agonist exhibited significant analgesic effects.

MeSH terms

  • Analgesics / chemical synthesis
  • Analgesics / chemistry*
  • Analgesics / therapeutic use
  • Animals
  • Disease Models, Animal
  • Freund's Adjuvant / pharmacology
  • Humans
  • Hyperalgesia / drug therapy
  • Pyridines / chemical synthesis
  • Pyridines / chemistry*
  • Pyridines / therapeutic use
  • Rats
  • Receptor, Cannabinoid, CB1 / agonists*
  • Receptor, Cannabinoid, CB1 / metabolism
  • Receptor, Cannabinoid, CB2 / agonists*
  • Receptor, Cannabinoid, CB2 / metabolism

Substances

  • Analgesics
  • Pyridines
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • Freund's Adjuvant
  • pyridine